Balancing Treg Biology, Profitability & Patient Needs to Drive Smart Indication Selection

  • Highlighting the key considerations guide indication selection for Treg therapies
  • Exploring the success of antigen specific Treg trafficking to key disease areas to effectively evaluate treatment efficacy and guide indication selection
  • Assessing opportunities for leveraging Treg bystander effects to enhance immune modulation across multiple conditions
  • Considering how preclinical model availability influences indication strategies, from narrow focus to broader applications